The genome sequencing technology provider has boosted its total funding to approximately $124m, Sinopharm and China General Technology Group having backed a $38.7m round.
China-based genome sequencing technology developer Yikon Genomics has received RMB250m ($38.7m) of series D funding from investors including pharmaceutical firm Sinopharm and Chinese state-owned conglomerate China General Technology Group, DealStreetAsia has reported.
The round also featured private equity firm Yunfeng Capital, investment firm Oriza Holdings and investment bank China International Capital Corporation’s CICC Capital subsidiary, which invested through CICC Qide Innovation Biopharmaceutical Equity Investment Fund.
Sinopharm participated in the round through its corporate venturing unit, Sinopharm Capital, while China General…
